Torrent Pharmaceuticals Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-a371d34157c95443a57ef3ab.pdf

Key Takeaways


India Branded Business: The Growth Engine Fires on All Cylinders

Sudhir Menon: “As long as the supply situation remains the same for us and the competition, there's no additional bottlenecks that come up, my sense is that the market share should not change materially, materially from here.”

JB Pharma Integration: Synergies Arriving Early, Revenue Impact Contained

Aman: “While this will not have an impact anything close to what was seen in Q4, there could be a minor and transient impact in revenues in some territories until the integration is completed over the next 2 to 3 quarters.”

Semaglutide: Supply Shock Derails the Trajectory, Not the Thesis

Sudhir Menon: “Given now that we're faced with the situation, that's definitely not going to be possible. But we would rather wait for another quarter to see how our relaunch of the, the loss SKUs, how quickly they can regain share, and then we can get back with what the annual number could be.”

International Markets: US Turns the Corner, Germany and Brazil Weigh

MarketTrendCommentary
US▲ Inflecting23% constant currency growth from new launches achieving target share and one-time opportunities; 17 launches over 30 months contributing ₹2–2.5 crore largely compensate for price erosion; will be profitable this year after five years of losses.
Brazil▼ Headline soft, underlying strongIQVIA secondary sales grew 19% vs market 4%, but primary sales were inferior due to a one-time channel inventory reduction as distributors sought extended credit amid rising interest rates; normalized mid-teens growth expected to return.
Germany▼ Still struggling9% constant currency decline from a twofold challenge: a prominent supplier contributing 10–15% of revenue is out of business, and the company still gets outbid in tenders despite cost-reduction efforts.
JB International▬ RecoveringShould recover post-changes; high single-digit to low double-digit constant currency growth for the full year should be possible.
Sudhir Menon: “I can't say we are out of the woods in Germany. I would say right now we are, you know, still in the middle of the woods.”

Margins: Gross Margin Gains Fund the Investment Cycle


Capital Allocation: India First, Patience on M&A

Sudhir Menon: “Our preference is that if we have the same size opportunity in front of us in India versus international, regardless of how big or small, it will always be India first.”

Guidance & Commitments

CommitmentSpecificsTimeline
JB India branded growthDouble-digit revenue growth for full yearFY27
JB International growthHigh single-digit to low double-digit constant currency growthFY27
Integration revenue impactMinor and transient; normalization expectedBy Q4 FY27
Cost synergiesFirst-year number “definitely going to be above 100” (vs original ₹90 crore); incremental quarterly improvementFY27
Base business EBITDA marginAt least 0.5% improvement per year over prior yearFY27
US profitabilityWill be profitable this year, at least will not subtract from bottom lineFY27
Semaglutide annual guidanceRevised number to be provided after observing relaunched SKU share recaptureNext quarter
Combined entity margin guidanceFull-year margin guidance for merged entityNext quarter
Capital allocationNo next opportunity considered until JB integration comfort is achieved12–18 months
Leverage ceilingNot above 3x–3.5x net debt-to-EBITDAOngoing

Key Metrics

MetricQ1 FY27
Consolidated revenue₹4,921 cr, up 55% YoY
Operating EBITDA₹1,664 cr, up 61% YoY
Operating EBITDA margin33.8%
Base business revenue growth17% YoY
Base business operating EBITDA₹1,240 cr, up 20% YoY
Base business EBITDA margin33.3%
Base business gross margin~78%, versus ~76–76.5% last year
India base business revenue₹2,157 cr, 19% growth vs IPM growth of 12%
India base business volume growth5.1% vs IPM volume growth of 2%
India base business price growth7.7% vs IPM price growth of 5.8%
India base business new product contribution~6% vs IPM new product growth of 3.8%
JB business revenue₹1,201 cr, up 10% YoY
JB business EBITDA margin35.3%, improvement of more than 6% YoY
JB India branded business growth13%
JB international business growth12%
Brazil constant currency revenueBRL 14.7 cr, 3% YoY growth; IQVIA growth at 19%
Brazil generics share of sales~22%
US constant currency revenue$44 million, up 23% YoY
Germany constant currency revenue€2.9 cr, down 9% YoY
Curation business growth34%
Semaglutide franchise India Q1 market share36% (oral and injectable combined)
Semaglutide oral market share in June94%
Semaglutide combined Q1 sales₹50 cr
Semaglutide full-year target₹250 cr (on track before supply issue)
Combined field force strength9,400 (base: 7,200, JB: 2,200)
Combined PCPMJust over ₹10 lakhs
JB field force attrition16% in June, down from nearly 30% pre-acquisition
Net debt to EBITDA2.07x (on underlying combined EBITDA)
First-year synergy targetAbove ₹100 cr (original target ₹90 cr)
Brands above ₹100 cr28